News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Sep 05, 2002

Sep 05, 2002

Acambis reports successful phase I trial of cell-culture-grown smallpox vaccine

(CIDRAP News) Ð The smallpox vaccine being produced by Acambis plc for the US government as part of the nation's bioterrorism preparedness program worked well in a Phase I trial, Acambis officials announced this week.

The vaccine, called ACAM1000, generated a characteristic skin lesion or "take" in all those vaccinated, and there were no serious or unusual side effects, the company reported in a Sep 3 news release.

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»